Jason Brenner, MD
Ophthalmology · Brookline, MANPI 1750674719
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Alcon accounts for 72.9% of it on its own, with 29 other manufacturers making up the rest. Among ophthalmology clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 318 payments — averaging $96.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$22K
- Glaukos Corporation$2K
- AbbVie$1K
- Tarsus Pharmaceuticals, Inc.$672
- Lensar, Inc.$650
- Novartis$502
- plus $3K from 24 others
Across 15 payments — averaging $1453.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rxsight Inc$22K
What the payments were for
- Consulting fees$18,28160%
- Speaking & faculty fees$510%
- Travel & lodging$2,3608%
- Food & beverage$9,96332%
- Gifts$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 105 | $22,373 |
| Glaukos Corporation | 11 | $2,219 |
| AbbVie(2 entities) | 68 | $1,135 |
| Tarsus Pharmaceuticals, Inc. | 25 | $672 |
| Lensar, Inc. | 1 | $650 |
| Novartis | 23 | $502 |
| Alcon Research LLC | 1 | $456 |
| Amgen(2 entities) | 16 | $350 |
| Sun Pharmaceutical Industries Inc. | 9 | $263 |
| Sight Sciences, Inc. | 5 | $237 |
| Rxsight Inc | 7 | $234 |
| Dompe US, Inc. | 7 | $191 |
| Eyepoint US, Inc. | 2 | $173 |
| Oyster Point Pharma, Inc. | 5 | $157 |
| Rayner Intraocular Lenses Limited | 6 | $147 |
| Lumenis BE Inc | 1 | $144 |
| Bausch & Lomb Americas Inc. | 7 | $143 |
| Beaver-visitec International, Inc. | 1 | $128 |
| Carl Zeiss Meditec USA, Inc. | 2 | $121 |
| Aerie Pharmaceuticals, Inc. | 2 | $117 |
| Mallinckrodt Enterprises LLC | 3 | $61 |
| Optovue, Inc. | 2 | $57 |
| Harrow Eye, LLC | 2 | $50 |
| ANI Pharmaceuticals, Inc. | 1 | $30 |
| Mallinckrodt Hospital Products Inc. | 1 | $26 |
| Thea Pharma Inc. | 1 | $15 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $15 |
| Ocular Therapeutix, Inc. | 1 | $14 |
| Omeros Corporation | 1 | $12 |
| Kala Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wavelight Refractive Suite$15,136
- WaveLight EX500 Excimer Laser$3,178
- Wavelight$3,171
- LenSx$1,105
- LENSAR LASER SYSTEM$650
- Wavelight Plus$147
- M22$144
- TearCare$142
- TRYPTYR$139
- Clareon PanOptix Pro$129
- DURYSTA$125
- DEXYCU$114
- RESTASIS$111
How this compares
$30,700 in reported general payments places this provider in the 90th percentile of 653 ophthalmology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 65 | $54,330 |
| LumiganBimatoprost | 44 | $25,897 |
| XdemvyLotilaner | 12 | $21,733 |
| XiidraLifitegrast | 18 | $21,655 |
| VyzultaLatanoprostene Bunod | 29 | $14,771 |
| Cyclosporine | 32 | $12,460 |
| CombiganBrimonidine Tartrate/Timolol | 21 | $8,845 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 35 | $5,996 |
| Ketorolac Tromethamine | 254 | $5,599 |
| Loteprednol Etabonate | 25 | $5,470 |
| Brimonidine Tartrate | 76 | $3,917 |
| Prednisolone Acetate | 73 | $3,643 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 59 | $3,425 |
| Latanoprost | 199 | $3,000 |
| Brinzolamide | 14 | $2,732 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $1,135 | $89,072130 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $143 | $36,42647 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $672 | $21,73312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 653 ophthalmology providers in Massachusetts.
Other ophthalmology in Brookline
- Mark HughesBrookline$145K
- Reena GuptaBrookline$36K
- Rishi SinghBoston$1.7M
- Peter ChangWaltham$992K
- Stephen AnesiWaltham$922K
- David LallySpringfield$328K
- Adam RogersBoston$316K
- Bonnie HendersonBoston$279K
- Mark LatinaReading$279K
- Dean EliottBoston$250K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.